Tests a GLP-1 drug for nerve damage in multiple sclerosis
Tests a GLP-1 receptor agonist in adults with multiple sclerosis to study nerve damage.
Plain-language title generated from the registry record
Registry title: Effects of GLP-1 analogue in multiple sclerosis
Key facts
- Where
- Bratislava, SlovakiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT01444833, who can take part
Where in Slovakia
- Comenius University BratislavaBratislava, SlovakiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Comenius University Bratislava
- Trial code
- NCT01444833EU 2024-519235-42-00
- Record updated
- 7 November 2024
- Original description
Primary objectives To determine the effect of a GLP-1 receptor agonist on chronic axonal damage and neurodegeneration in MS patientsRead full original descriptionShow less
Effects of GLP-1 analogue in multiple sclerosis
Primary objectives To determine the effect of a GLP-1 receptor agonist on chronic axonal damage and neurodegeneration in MS patients
Inclusion: Main inclusion criteria • Must freely consent to participate in this trial and personally sign the informed consent prior to performing any procedure in this study. • Male or female aged 18 to 60 years (inclusive) at the time of the first visit to this study. • Able to understand the requirements and follow the procedures within this study. • Patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis, with a worse prognosis due to higher disease activity, with a disease duration of at least 1 year • EDSS<5, • Set on stable treatment of the underlying disease for at least three (3) months.
Exclusion: Main • diabetes mellitus on diet, oral antidiabetic drugs or insulin • other serious chronic diseases • Acute pancreatitiswith a historyof • oncological diseases • long-term use of medications such as glucocorticoids, Antidepressants • Severe renal impairment and kidney disease in the last stage. • Severe hepatic impairment. • Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transit ischemic attack in 90 days before the dateof screening. • New Class IV congestive heart failure York Heart Association (NYHA). • Historyof major surgical procedures involving the stomach or smallintestine potentially affecting the absorption of medicinal products and/or nutrients, as assessed by the • Pregnancy • breastfeeding • Drug use or alcoholuse • the presence of metal components in the body • Known hypersensitivity to the investigational drug, excipients or hypersensitivity to a drug with a similar structure.